Capstone therapeutics corp. CAPS.US Overview

BetaUS StockHealthcare

(No presentation for CAPS)

CAPS AI Analysis & Strategy

Value: 2

With subpar financial data, the company currently shows lower growth.

Dividend: 1

No dividend distribution record.

Analysis Conclusion

The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.

CAPS Current Performance

-0.66%

Capstone therapeutics corp.

0.98%

Avg of Sector

0.83%

S&P500

CAPS Key Information

CAPS Financial Forecast

Unit : USD

CAPS Earnings Table

No related data records

CAPS Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.